Erasca (ERAS) Adds 13%; Soars 310% YTD

Erasca Inc. (NASDAQ:ERAS) is one of the 10 Stocks Dominating Today’s Market Action.

Erasca rallied for a second day on Thursday, jumping 13.04 percent to close at $15.26 apiece on strong investor optimism, backed by earlier optimistic coverage from several analysts.

Year-to-date, the company has already seen its stock price soar by 310 percent, making it one of the top-performing stocks this year.

Investors are also positioning portfolios ahead of initial data from clinical trials to test the efficacy of its treatment candidate, ERAS-0015, in patients with RAS-mutant solid tumors in the US and China.

Erasca (ERAS) Adds 13%; Soars 310% YTD

Photo by RDNE on Pexels

In January this year, ERAS-0015 showed early promising results in one of Erasca Inc.’s (NASDAQ:ERAS) clinical studies, particularly during dose escalations.

According to the company, it saw two confirmed partial responses and one unconfirmed partial response during the clinical study of its pan-RAS molecular glue degrader ERAS-0015.

In addition, more unconfirmed responses were observed in patients taking 8 mg doses, with consistent, linear pharmacokinetics across all dose levels evaluated and no evidence of exposure plateau so far.

While we acknowledge the risk and potential of ERAS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ERAS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.